Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer

G Petroni, LC Cantley, L Santambrogio… - Nature Reviews …, 2022 - nature.com
A variety of targeted anticancer agents have been successfully introduced into clinical
practice, largely reflecting their ability to inhibit specific molecular alterations that are …

DNA repair inhibitors: potential targets and partners for targeted radionuclide therapy

H Obata, M Ogawa, MR Zalutsky - Pharmaceutics, 2023 - mdpi.com
The present review aims to explore the potential targets/partners for future targeted
radionuclide therapy (TRT) strategies, wherein cancer cells often are not killed effectively …

STING enhances cell death through regulation of reactive oxygen species and DNA damage

TJ Hayman, M Baro, T MacNeil, C Phoomak… - Nature …, 2021 - nature.com
Resistance to DNA-damaging agents is a significant cause of treatment failure and poor
outcomes in oncology. To identify unrecognized regulators of cell survival we performed a …

Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial

P Loap, D Loirat, F Berger, M Rodrigues… - Jama …, 2022 - jamanetwork.com
Importance Triple-negative breast cancer (TNBC) cells are sensitive to poly (adenosine
diphosphate ribose) polymerase (PARP) inhibitors used as radiosensitizers. Whether …

Short-term CDK4/6 inhibition radiosensitizes estrogen receptor–positive breast cancers

AM Pesch, NH Hirsh, BC Chandler… - Clinical Cancer …, 2020 - AACR
Abstract Purpose: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have improved
progression-free survival for metastatic, estrogen receptor–positive (ER+) breast cancers …

Tailoring treatment for patients with inflammatory breast cancer

AB Newman, F Lynce - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement Inflammatory breast cancer (IBC) is a rare but aggressive subtype of
breast cancer that has a propensity for locoregional recurrence and distant metastasis and is …

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer

KM Jungles, EA Holcomb, AN Pearson… - Frontiers in …, 2022 - frontiersin.org
Breast cancer is the most prevalent non-skin cancer diagnosed in females and develo**
novel therapeutic strategies to improve patient outcomes is crucial. The immune system …

Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer

L Wang, L Yu, J Shi, F Li, C Zhang, H Xu, X Yin… - Scientific reports, 2022 - nature.com
Differences in genetic molecular features including mutation, copy number alterations and
DNA methylation, can explain interindividual variability in response to anti-cancer drugs in …

Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition

G Raspaglio, M Buttarelli, F Filippetti, A Battaglia… - Cell Death & …, 2021 - nature.com
Cervical cancer (CC) is the fourth most common cause of cancer-related death in women.
According to international guidelines, a standard treatment for locally advanced cervical …

NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers

F Bertucci, C Rypens, P Finetti, A Guille… - Molecular …, 2020 - Wiley Online Library
Inflammatory breast cancer (IBC) is the most pro‐metastatic form of breast cancer. Better
understanding of its pathophysiology and identification of actionable genetic alterations …